Chinese Firms Account for Over a Quarter of the Late-Stage mAb Pipeline
Late-stage clinical mAbs by company, number of candidates
Bar chart of late-stage clinical monoclonal antibody candidates by company, where AstraZeneca leads with 5 candidates and Chinese firms including Shanghai Hengrui, Sichuan Baili, and others collectively account for approximately 26 percent of the total pipeline.
